Haviland Kate

USNatural personDirector

Insider

Haviland Kate

USNatural personDirector3 companies · 24mo

Transactions

167

Issuers

Buys / Sells

1/75

Last tx

17 Jul 2025

Current positions

Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.

Issuer	Shares	Source	Last tx	Detail
Fulcrum Therapeutics, Inc.	36,000	reported	26 Jun 2025	tx 7+148,570
Bicara Therapeutics Inc.	23,746	reported	09 Jun 2025	tx 2+47,492
Blueprint Medicines Corp	0	reported	17 Jul 2025	tx 161+1,050,218−1,062,932

Recent transactions

Date	Type	Issuer	Qty	Price	Signals
17 Jul 2025	GRANT_AWARD	Blueprint Medicines Corp	129,210	—
17 Jul 2025	TENDER	Blueprint Medicines Corp	70,729	—
17 Jul 2025	OTHER	Blueprint Medicines Corp	224,410	—
17 Jul 2025	OTHER	Blueprint Medicines Corp	2	—	deriv
17 Jul 2025	OTHER

InsiderLens aggregates public information issued by financial regulators (SEC, AMF, FCA, BaFin, AFM, FI, HKEX, ASX). The service constitutes neither investment advice nor a recommendation to buy or sell. Past performance is no guarantee of future results. Investing in financial instruments carries the risk of capital loss.

Current positions

Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.

Issuer	Shares	Source	Last tx	Detail
Fulcrum Therapeutics, Inc.	36,000	reported	26 Jun 2025	tx 7+148,570
Bicara Therapeutics Inc.	23,746	reported	09 Jun 2025	tx 2+47,492
Blueprint Medicines Corp	0	reported	17 Jul 2025	tx 161+1,050,218−1,062,932

Recent transactions

Date	Type	Issuer	Qty	Price	Signals
17 Jul 2025	GRANT_AWARD	Blueprint Medicines Corp	129,210	—
17 Jul 2025	TENDER	Blueprint Medicines Corp	70,729	—
17 Jul 2025	OTHER	Blueprint Medicines Corp	224,410	—
17 Jul 2025	OTHER	Blueprint Medicines Corp	2	—	deriv
17 Jul 2025	OTHER